metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genot...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance
Deanna D. Hilla,
Corresponding author
deanna.hill@merck.com

Corresponding author.
, Jennifer R. Kramerb,c, Kassie R. Chaffinb, T. Christopher Masta, Michael N. Robertsona, Fasiha Kanwalb,c, Barbara A. Habera
a Merck & Co., Inc., Rahway, NJ, United States
b Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX, United States
c Department of Medicine, Baylor College of Medicine, Houston, TX, United States
Read
678
Times
was read the article
99
Total PDF
579
Total HTML
Share statistics
Article information
ISSN: 16652681
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 December 19 2 21
2024 November 36 6 42
2024 October 23 2 25
2024 September 31 0 31
2024 August 21 5 26
2024 July 23 3 26
2024 June 29 1 30
2024 May 25 2 27
2024 April 18 9 27
2024 March 30 6 36
2024 February 36 10 46
2024 January 39 1 40
2023 December 17 4 21
2023 November 15 3 18
2023 October 23 5 28
2023 September 13 3 16
2023 August 11 1 12
2023 July 10 1 11
2023 June 27 3 30
2023 May 50 1 51
2023 April 45 4 49
2023 March 33 10 43
2023 February 5 10 15
2023 January 0 7 7
Show all

Follow this link to access the full text of the article

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos